Skip to content

Efficacy Evaluation of Jianpi Tiaqi Huayu Decoction Combined with Qingfei Paidu Decoction in Improving Prognosis of Viral Pneumonia in Patients Undergoing Chemotherapy for Tumors

Evaluation of the efficacy of Jianpi Qiaohuayu Formula combined with Qingfei Paidu Decoction in improving the prognosis of viral pneumonia in chemotherapy patients with tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001024
Enrollment
Unknown
Registered
2026-04-17
Start date
2026-04-18
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Viral pneumonia

Interventions

Research Group:In addition to Western medicine for specific symptoms, Jianpi Qiaohuayu Decoction combined with Qingfei Putuoxin Decoction is administered orally, twice daily, 100ml each time.
Control Group:Receive standard Western medicine for symptomatic treatment, with dosage and administration the same as the research group.

Sponsors

Second Affiliated Hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1) The patient meets the diagnostic criteria for viral pneumonia. 2) Patients who have undergone chemotherapy for malignant tumors within one week. 3) The patient's TCM syndrome type is spleen qi deficiency with blood stasis syndrome. 4) The patient's age is greater than or equal to 18 years old. 5) Written informed consent must be obtained from the patient or their legal guardian.

Exclusion criteria

Exclusion criteria: 1) Patients with acute exacerbation of pulmonary fibrosis or tuberculosis. 2) Patients with severe mental illness, human immunodeficiency virus (HIV) infection, acquired immunodeficiency syndrome (AIDS), or autoimmune diseases. 3) Patients with severe gastrointestinal diseases (e.g., perforation infection, Crohn's disease, ulcerative colitis). 4) Patients with severe cardiovascular diseases (e.g., myocardial infarction, heart failure (NYHA III–IV), stroke, uncontrolled hypertension (systolic =180 mmHg and/or diastolic =110 mmHg), liver or kidney failure, or hematologic disorders). 5) Patients who experienced cardiogenic shock, acute myocarditis, uncontrolled malignant arrhythmias, hypertrophic obstructive cardiomyopathy, severe valvular disease requiring surgical treatment, or pulmonary artery embolism within the past 3 months or during the study period. 6) Pregnant women, breastfeeding women, or women planning pregnancy within 3 months.

Design outcomes

Primary

MeasureTime frame
turnover rate;Time to negativity;Scoring of the Effectiveness Evaluation Scale for the Treatment of Viral Pneumonia with Traditional Chinese Medicine (TCM);

Secondary

MeasureTime frame
Hospitalization Duration;Blood Routine;C-reactive protein;Procalcitonin;Immune indicators;Imaging examinations;

Countries

China

Contacts

Public ContactYao Qinghua

Zhejiang University of Traditional Chinese Medicine Affiliated Second Hospital (Zhejiang Province Xinhua Hospital)

20234052@zcmu.edu.cn13588899111

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026